Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Teva Pharmaceutical Industries Ltd
(NY:
TEVA
)
15.09
USD
+0.18 (+1.19%)
Streaming Delayed Price
/ Updated:
10:00 AM EDT, Apr 24, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
1,324,845
Open
15.05
Bid (Size)
15.08 (21)
Ask (Size)
15.09 (15)
Prev. Close
14.91
Today's Range
14.85 - 15.13
52wk Range
14.04 - 25.96
Shares Outstanding
1,018,482,488
Dividend Yield
0.48%
Performance
YTD
-4.81%
-4.81%
1 Month
-10.78%
-10.78%
3 Month
-19.58%
-19.58%
6 Month
-29.07%
-29.07%
1 Year
-15.81%
-15.81%
Top News
More News
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
April 23, 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A...
Read More
from
Business Wire News Releases
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
April 22, 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Read More
from
Business Wire News Releases
More News
Read More
Biotech Brief: Optimism Rising for Cancer Treatment Advancements in 2019
April 17, 2019
from
PR Newswire
Biotech Brief: Optimism Rising For Cancer Treatment Advancements In 2019
April 17, 2019
category
Featured News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States
April 11, 2019
from
Business Wire News Releases
Why International Regulations on Clinical Trials can Actually Reduce Costs and Shorten Time to Market
April 11, 2019
from
PR Newswire
Why International Regulations On Clinical Trials Can Actually Reduce Costs And Shorten Time To Market
April 11, 2019
category
Featured News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
UPDATE 2-Teva stops testing its migraine drug as cluster headache treatment
April 23, 2019
category
companyNews
from
Reuters: Company News
UPDATE 1-Teva scraps cluster headache program
April 23, 2019
category
companyNews
from
Reuters: Company News
Teva to stop developing cluster headache treatment
April 23, 2019
category
companyNews
from
Reuters: Company News
Why This Migraine-Focused Biotech Stock Could Be The Next Takeover
April 23, 2019
from
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password
